[1]路荣梅 李锦新 李连涛 陈 刚 温俊平.10例Gitelman综合征患者临床表现特点和基因突变分析[J].福建医药杂志,2020,42(02):24-29.
　LU Rongmei,LI Jinxin,LI Liantao,et al.Analysis of the clinical features and gene mutations of ten patients with Gitelman syndrome[J].FUJIAN MEDICAL JOURNAL,2020,42(02):24-29.
点击复制

10例Gitelman综合征患者临床表现特点和基因突变分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年02期
页码:
24-29
栏目:
临床研究
出版日期:
2020-04-15

文章信息/Info

Title:
Analysis of the clinical features and gene mutations of ten patients with Gitelman syndrome
文章编号:
1002-2600(2020)02-0024-06
作者:
路荣梅 李锦新 李连涛 陈 刚 温俊平1
福建省立医院内分泌科(福州 350001)
Author(s):
LU Rongmei; LI Jinxin; LI Liantao; CHEN Gang; WEN Junping.
Department of Endocrinology, Fujian Provincial Hospital, Fuzhou,Fujian 350001,China
关键词:
Gitelman综合征;  临床表现;  基因型;  基因诊断
Keywords:
Gitelman syndrome;  clinical phenotype;  genotype;  genetic diagnosis
分类号:
R446.1
文献标志码:
A
摘要:
目的 分析Gitelman综合征(Gitelman syndrome,GS)患者临床表现特点和基因突变类型。方法 在分析10例GS患者临床表现和实验室相关检查结果的基础上,对其进行GS致病基因——SLC12A3基因突变位点的检测。首先在获得患者知情同意书后抽取其外周血提取基因组DNA,然后通过聚合酶链式反应(polymerase chain reaction,PCR)扩增目的基因的26个外显子及其侧翼序列,最后采用sanger测序结合DNassist序列比对软件进行序列分析来确定突变位点。结果 本研究共检测出13种致病突变,没有出现明显的热点突变位点,其中错义突变8种(61.5%),缺失突变3种(23.1%),内含子剪接位点突变2种(15.4%)。10例临床疑似患者中5例为复合杂合致病,占比50%; 2例为纯合致病,占比20%; 其余3例仅检出一处杂合致病突变位点。结论 本研究检测到新的突变位点D62G、C146Y,其致病性未见相关文献报道,除此之外,本研究还发现GS临床表现与基因型之间并没有非常明确的关系,故临床上目前还不能通过基因型来判断患者疾病的严重程度和发展趋势。但是,基因诊断仍然是该病诊断的金标准,它除了可以确诊疾病,还可以实现疾病的早期筛查和产前的优生优育。
Abstract:
Objective To analyze the clinical features and gene mutations of Gitelman syndrome.Methods Based on the clinical symptoms and laboratory test results,this study analyzed the mutations of disease-causing gene SLC12A3 in 10 patients with Gitelman syndrome.After getting the informed consent of patients, the genomic DNA of peripheral blood was extracted.The 26 exons and their flanking sequences of SLC12A3 were amplified by polymerase chain reaction(PCR).Sanger sequencing was combined with DNassist sequence alignment software to confirm the mutations.Results In this study, we found 13 kinds of pathogenic mutations altogether.There was no hot spot mutation.There were eight kinds of missense mutations(61.5%), three kinds of deletion mutations(23.1%), and two kinds of splicesite mutations(15.4%).Among the ten clinical suspected patients, five cases were caused by compound heterozygous mutation, accounting for 50%.Two cases were homozygous mutation, accounting for 20%.Only one heterozygous pathogenic mutation was detected in the rest of patients.Conclusion In this study,two new mutation sites, D62G and C146Y, were founded, and their pathogenicity has not been reported.Beyond that,we found the relationship between phenotype and genotype was not clear.So we cant estimate the severity and advancing of the disease according to the genotype.However, genetic diagnosis is also the gold standard for this disease.In addition to diagnose disease, it can also achieve early screening and prenatal diagnosis.

参考文献/References:

[1] Calo L A, Maiolino G.Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartters and Gitelmans syndromes[J].J Endocrinol Invest, 2015,38(7):711-716.
[2] Blanchard A, Bockenhauer D, Bolignano D, et al.Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes(KDIGO)Controversies Conference[J].Kidney international, 2017,91(1):24-33.
[3] Gitelman H J, Graham J B, Welt L G.A new familial disorder characterized by hypokalemia and hypomagnesemia[J].Transactions of the Association of American Physicians, 1966,79:221-235.
[4] Pagnin E, Ravarotto V, Maiolino G,et al.Galphaq/p63Rho-GEF interaction in RhoA/Rho kinase signaling: investigation in Gitelmans syndrome and implications with hypertension[J].J Endocrinol Invest, 2018,41(3):351-356.
[5] Naesens M, Steels P, Verberckmoes R.Bartters and Gitelmans syndromes: from gene to clinic[J].Nephron Physiology, 2004,96(3):65-78.
[6] Blanchard A, Vallet M, Dubourg L, et al.Resistance to insulin in patients with Gitelman syndrome and a subtle intermediate phenotype in heterozygous carriers: a cross-sectional study[J].Journal of the American Society of Nephrology, 2019,30(8):1534-1545.
[7] Liu T, Wang C, Lu J,et al.Genotype/Phenotype Analysis in 67 Chinese Patients with Gitelmans Syndrome[J].American Journal of Nephrology, 2016,44(2):159-168.
[8] 陈清石.Gitelman综合征3例的临床及基因诊断分析[D].福州:福建医科大学, 2013.
[9] Riveira-Munoz E, Chang Q, Godefroid N, et al.Transcrip-tional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome[J].Journal of the American Society of Nephrology, 2007,18(4):1271-1283.
[10] Lu Q, Zhang Y, Song C, et al.A novel SLC12A3 gene homozygous mutation of Gitelman syndrome in an Asian pedigree and literature review[J].J Endocrinol Invest, 2016,39(3):333-340.
[11] Konrad M, Weber S.Recent advances in molecular genetics of hereditary magnesium-losing disorders[J].Journal of the American Society of Nephrology, 2003,14(1):249-260.
[12] Fujimura J, Nozu K, Yamamura T, et al.Clinical and genetic characteristics in patients with Gitelman syndrome[J].Kidney International Reports, 2019,4(1):119-125.
[13] Matsunoshita N, Nozu K, Shono A, et al.Differential diagno-sis of Bartter syndrome, Gitelman syndrome, and pseudo-Bartter/Gitelman syndrome based on clinical characteristics[J].Genetics in medicine, 2016,18(2):180-188.
[14] Colussi G, Bettinelli A, Tedeschi S, et al.A thiazide test for the diagnosis of renal tubular hypokalemic disorders[J].Clinical journal of the American Society of Nephrology, 2007,2(3):454-460.
[15] Fukuyama S, Hiramatsu M, Akagi M,et al.Novel mutations of the chloride channel Kb gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria[J].J Clin Endocrinol Metab, 2004,89(11):5847-5850.
[16] Nakamura A, Shimizu C, Nagai S, et al.Problems in diagno-sing atypical Gitelmans syndrome presenting with normomagnesaemia[J].Clinical endocrinology, 2010,72(2):272-276.
[17] Schnoz C, Carrel M, Loffing J.Loss of sodium chloride co-transporter impairs the outgrowth of the renal distal convoluted tubule during renal development[J].Nephrol Dial Transplant,2020,35(3):411.
[18] 秦岭, 邵乐平, 任红, 等.中国人Gitelman综合征高发突变的基因型和表型特征[J].肾脏病与透析肾移植杂志, 2008,17(4):331-334.
[19] Gamba G.Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters[J].Physiological reviews, 2005,85(2):423-493.
[20] Zhong F, Ying H, Jia W, et al.Characteristics and Follow-Up of 13 pedigrees with Gitelman syndrome[J].Journal of Endocrinological Investigation, 2019,42(6):653-665.
[21] Larkins N, Wallis M, McGillivray B,et al.A severe pheno-type of Gitelman syndrome with increased prostaglandin excretion and favorable response to indomethacin[J].Clinical Kidney Journal, 2014,7(3):306-310.

备注/Memo

备注/Memo:
基金项目:福建省卫生计生委青年课题(2017/1/4)1 通信作者,Email:junpingwen@163.com
更新日期/Last Update: 2020-04-15